DHC CONTINUS
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
31-03-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
DIHYDROCODEINE BITARTRATE
Available from:
Napp Pharmaceuticals Limited
Dosage:
120 Milligram
Pharmaceutical form:
Tablets
Authorization date:
1995-04-19
Summary of Product characteristics
License
Part II
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
DHC Continus Prolonged-release Tablets 120 mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Dihydrocodeine Tartrate 120 mg
For excipients, see 6.1
3 PHARMACEUTICAL FORM
Prolonged release tablet.
White to off-white, capsule-shaped, biconvex tablet with DHC 120 on one side.
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
As an analgesic in the relief of moderate to severe pain.
4.2 Posology and method of adminstration
Adults only
One tablet 12 hourly.
Elderly
Reduced dosage or increased intervals between doses may be required.
Route of Administration
Oral.
4.3 Contraindications
DHC CONTINUS tablets should not be used in patients hypersensitive to the active ingredient or any of the other
constituents of the product or in patients with respiratory depression or obstructive airways disease. As dihydrocodeine
may cause the release of histamine it should not be given during an attack of asthma. Patients with rare hereditary
problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this
medicine.
4.4 Special warnings and special precautions for use
Prolonged use of high dosage may induce dependence with a withdrawal syndrome on discontinuation. Repeated use
may result in the development of tolerance. DHC CONTINUS tablets should be
Read the complete document
